• Review|Open Access

    Management of metastatic esophagogastric junction adenocarcinoma

    Tasuku Toihata , Yu Imamura , Masayuki Watanabe , Hideo Baba
    The prognosis of metastatic disease of esophagogastric junction adenocarcinoma remains poor, despite using a variety of regimens using cytotoxic agents. Recent understanding of molecular characteristic and tumor microenvironment of this cancer is currently instigating new therapeutic options. In this review, we summarized previous evidences of cytotoxic agents widely used worldwide, and updated recent developments of molecular targeted drugs, and immune checkpoint inhibitors. Read more
    This article belongs to the Special Issue Reviews of Gastric Cancer Metastasis and Treatment
    J Cancer Metastasis Treat 2018;4:24. | doi:10.20517/2394-4722.2017.82
    Published on: 17 May 2018  | Viewed:54  | Downloaded:2
    +HTML| PDF
  • Review|Open Access

    Treatment strategy for metastatic gastric cancer in Japan

    Kojiro Eto , Satoshi Ida , Masayuki Watanabe , Hideo Baba
    Despite recent progress in diagnostic imaging, gastric cancer (GC) is occasionally found at an advanced stage with distant metastasis. As metastatic GC is difficult to cure, the treatment strategy should be considered individually based on the physical and socioeconomic status of patients as well as on the GC symptoms. The first choice of treatment for metastatic GC is chemotherapy, and several chemotherapeutic regimens for metastatic or recurrent GC have been developed through randomized controlled trials. Ongoing clinical trials will provide novel therapeutic options for patients with... Read more
    This article belongs to the Special Issue Reviews of Gastric Cancer Metastasis and Treatment
    J Cancer Metastasis Treat 2018;4:23. | doi:10.20517/2394-4722.2017.73
    Published on: 16 May 2018  | Viewed:78  | Downloaded:2
    +HTML| PDF
  • Review|Open Access

    Conversion surgery for stage IV gastric cancer

    Satoshi Ida , Masayuki Watanabe
    Gastric cancer with distant metastases, such as para-aortic lymph node metastases, hepatic metastases, and peritoneal dissemination, is classified as stage IV. In this situation, cancer cells have formed micrometastases throughout the body; therefore, according to the algorithm of the Japanese guidelines, stage IV cancer is outside the indication for curative resection. Recent advances in some chemical agents have been remarkable, and some patients have survived for long periods even with stage IV gastric cancer. Thus, even in patients with stage IV gastric cancer, there is a possibility... Read more
    This article belongs to the Special Issue Reviews of Gastric Cancer Metastasis and Treatment
    J Cancer Metastasis Treat 2018;4:22. | doi:10.20517/2394-4722.2017.75
    Published on: 16 May 2018  | Viewed:105  | Downloaded:6
    +HTML| PDF
  • Original Article|Open Access

    The combined analysis of solid and liquid biopsies provides additional clinical information to improve patient care

    Ana Finzel , Helen Sadik , Gregori Ghitti , Jean-François Laes
    Aim: To investigate if the genetic information provided by sequencing of both solid and liquid biopsies can shed light on tumor heterogeneity, and to understand the clinical usefulness of adding blood profiling to standard tissue analysis in cancer care. Methods: Data from 351 patients with stage IV solid tumors for whom molecular profiling of their solid and liquid biopsies was available were studied, with a focus on the discrepant molecular information found between tissue and blood samples. Results: In 86% of patients, solid and liquid biopsies provided different molecular information.... Read more
    J Cancer Metastasis Treat 2018;4:21. | doi:10.20517/2394-4722.2018.10
    Published on: 8 May 2018  | Viewed:337  | Downloaded:27
    +HTML| PDF
  • Letter|Open Access

    Hypoxia in prostate cancer

    Peter Vaupel
    J Cancer Metastasis Treat 2018;4:20. | doi:10.20517/2394-4722.2018.30
    Published on: 7 May 2018  | Viewed:76  | Downloaded:6
    +HTML| PDF
  • Review|Open Access

    The role of long noncoding RNAs in cancer metastasis

    Christine Parsons , Alexis M. Tayoun , Benjamin D. Benado , Gabriel Ragusa , Rose F. Dorvil , Elizabeth A. Rourke , Kaitlyn O’ Connor , Irene G. Reed , Angela Alexander , Lian Willetts , Maryam Habibian , Brian D. Adams
    Signaling pathways are tightly controlled systems that regulate the appropriate timing of gene expression required for the differentiation of cells down a particular lineage essential for proper tissue development. Proliferation, apoptosis and metabolic pathways are just a few examples of the signaling pathways that require fine-tuning, so as to control the proper development of a particular tissue type or organ system. An estimated 70% of the genome is actively transcribed, only 2% of which codes for known protein-coding genes. Long noncoding RNAs (lncRNAs) in particular, are a large and... Read more
    J Cancer Metastasis Treat 2018;4:19. | doi:10.20517/2394-4722.2018.11
    Published on: 28 Apr 2018  | Viewed:485  | Downloaded:54
    +HTML| PDF
  • Review|Open Access

    Recent trend in gastric cancer treatment in the USA

    Kazuto Harada , Hideo Baba , Jaffer A. Ajani
    Gastric adenocarcinoma (GAC) is estimated as the fifteenth most common cancer in the USA. Incidence rate has been gradually decreasing, but prognosis remains dismal. For patients with locally advanced GAC (stage > T1B and < T4B), multimodality therapies, such as surgery, chemotherapy, and radiation therapy, are needed. Perioperative chemotherapy or postoperative chemoradiation/chemotherapy is recommended. For metastatic GAC patients, combination of two cytotoxics (platinum compound and fluoropyrimidine) has become a common place in the USA, and when HER2 is positive, trastuzumab is... Read more
    This article belongs to the Special Issue Reviews of Gastric Cancer Metastasis and Treatment
    J Cancer Metastasis Treat 2018;4:18. | doi:10.20517/2394-4722.2017.74
    Published on: 26 Apr 2018  | Viewed:347  | Downloaded:41
    +HTML| PDF
  • Review|Open Access

    Prostate cancer cells at a therapeutic gunpoint of the autophagy process

    Fabio Gabriele , Carolina Martinelli , Sergio Comincini
    In a normal prostate, the process of controling cell death is essential to maintain tissue homeostasis and its inhibition may lead to the development of cancer. Androgen receptor signaling plays pivotal roles in the prostate development and homeostasis as well as in the progression of prostate cancer. The main treatment for prostate cancer is a combination of androgen deprivation therapy (ADT) using anti-androgens and docetaxil administration. However, ADT eventually fails due to a pathological unbalance of cell death processes, in particular apoptosis and autophagy. As a result prostate... Read more
    This article belongs to the Special Issue Autophagy and Cancer: current biology and drug development
    J Cancer Metastasis Treat 2018;4:17. | doi:10.20517/2394-4722.2018.06
    Published on: 19 Apr 2018  | Viewed:296  | Downloaded:25
    +HTML| PDF
  • Meta-Analysis|Open Access

    The potential prognostic and predictive roles of programmed cell death protein 1 expressed by tumor-infiltrating lymphocytes in solid tumors: a meta-analysis

    Dong-Yun Zhang , Rong-Zhi Liu , Jian-Wei Ku , Yu-Hong Ma , Ying-Jie Yi
    Aim: Several previous studies have evaluated the potential role of programmed cell death protein 1 (PD-1) expressed by tumor-infiltrating lymphocytes (TILs) in various solid tumors and performed its prognosis role in patients’ survival with inconsistent results. This study aims to further systematically evaluate the association of PD-1 by TILs with clinicopathological parameters and clinical outcomes in solid tumor patients. Methods: A comprehensive search was conducted in PubMed, Embase, Web of Science, CNKI and Wanfang databases for relevant studies. The potential prognostic and... Read more
    J Cancer Metastasis Treat 2018;4:16. | doi:10.20517/2394-4722.2018.01
    Published on: 12 Apr 2018  | Viewed:381  | Downloaded:60
    +HTML| PDF
  • Original Article|Open Access

    Nodal involvement and p16-staining in upper alveolar ridge and hard palate cancer

    Edgar Salas , Pedro Sanchez , Juan Postigo , Carlos A. Castaneda , Miluska Castillo , Valeria Villegas , Luis Cano , Sandro Casavilca , Luis A. Bernabe , Carolina Belmar , Maria R. Villa-Robles , Raul Mantilla , Henry Guerra
    Aim: Upper alveolar ridge and hard palate squamous cancer is an infrequent malignancy. We evaluated factors associated with neck involvement and with p16-staining. Methods: Head and neck squamous-cell carcinoma (SCC) patients who went to Head and Neck Department between 1997 and 2011 were screened, and 73 resected upper alveolar ridge and 5 hard palate SCC were selected. Tumors with available tissue were stained with p16 immunohistochemistry. Results: Median age was 64.4 years, 55.1% were female, and 73.1% were in clinical stage IV. Neck dissections were performed in 24 and pathologically... Read more
    J Cancer Metastasis Treat 2018;4:15. | doi:10.20517/2394-4722.2017.66
    Published on: 28 Mar 2018  | Viewed:519  | Downloaded:30
    +HTML| PDF
  • Review|Open Access

    The magnitude of benefit from adding taxanes to anthracyclines in the adjuvant settings of breast cancer: discussion of large trials and meta-analyses

    Osama H. Elzaafarany , Atlal Abusanad
    The taxanes family of chemotherapy, which includes paclitaxel and docetaxel, has been incorporated in the adjuvant breast cancer treatments since 1990s. Sequential and concurrent use of taxanes was investigated with anthracyclines in many adjuvant early breast cancer randomized clinical trials. Results from taxanes trials showed inconsistent benefits. However, several meta-analyses showed significant survival benefit of adding taxanes. In this review article, data were collected and summarized from eleven large randomized trials and three meta-analyses to show and discuss the magnitude of... Read more
    J Cancer Metastasis Treat 2018;4:14. | doi:10.20517/2394-4722.2017.55
    Published on: 15 Mar 2018  | Viewed:598  | Downloaded:44
    +HTML| PDF
  • Commentary|Open Access

    Targeting adenosine receptor 2B in triple negative breast cancer

    Carola A. Neumann , Kevin Levine , Steffi Oesterreich
    J Cancer Metastasis Treat 2018;4:13. | doi:10.20517/2394-4722.2017.60
    Published on: 15 Mar 2018  | Viewed:708  | Downloaded:58
    +HTML| PDF
  • Review|Open Access

    Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives

    Francesca Battaglin , Alberto Puccini , Madiha Naseem , Marta Schirripa , Martin D. Berger , Ryuma Tokunaga , Michelle McSkane , Taline Khoukaz , Shivani Soni , Wu Zhang , Heinz-Josef Lenz
    The treatment scenario of colorectal cancer (CRC) has been evolving in recent years with the introduction of novel targeted agents and new therapeutic strategies for the metastatic disease. An extensive effort has been directed to the identification of predictive biomarkers to aid patients selection and guide therapeutic choices. Pharmacogenomics represents an irreplaceable tool to individualize patients treatment based on germline and tumor acquired somatic genetic variations able to predict drugs response and risk of toxicities. The growing knowledge of CRC molecular characteristics and... Read more
    This article belongs to the Special Issue Cancer Pharmacogenomics
    J Cancer Metastasis Treat 2018;4:12. | doi:10.20517/2394-4722.2018.04
    Published on: 7 Mar 2018  | Viewed:1157  | Downloaded:118
    +HTML| PDF
  • Review|Open Access

    Current challenges and opportunities in treating hypoxic prostate tumors

    Declan J. McKenna , Rachel Errington , Klaus Pors
    Hypoxia is a well-established characteristic of prostate tumors and is now recognised as a major contributory factor to both tumor progression and increased resistance to therapy. One strategy to target hypoxic tumor cells is the development of hypoxia-activated prodrugs (HAPs), which are activated in low oxygen environments. Several HAPs have been developed but despite encouraging results from preclinical studies many of these have performed disappointingly in clinical trials. In the developing era of precision medicine, it is clear that more strategic deployment of these agents is... Read more
    This article belongs to the Special Issue How does the prostate cancer microenvironment affect the metastatic process and/or treatment outcome?
    J Cancer Metastasis Treat 2018;4:11. | doi:10.20517/2394-4722.2017.54
    Published on: 1 Mar 2018  | Viewed:1571  | Downloaded:155
    +HTML| PDF
  • Review|Open Access

    Microenvironment in the pathogenesis of gastric cancer metastasis

    Hiroshi Sawayama , Takatsugu Ishimoto , Hideo Baba
    Tumor tissues contain cancer cells, other cellular and non-cellular components. Tumor microenvironments consist of cancer cells and various types of stromal cells, cancer associated fibroblasts, bone marrow-derived cells, endothelial cells, and hematopoietic cells, mainly tumor-associated macrophages and tumor-infiltrating lymphocytes. Increasing recent evidence has demonstrated that alteration of tumor microenvironments is deeply implicated in tumor progression and metastasis in gastric cancer (GC) patients. Recent investigations have provided insights into the molecular mechanisms of the... Read more
    This article belongs to the Special Issue Reviews of Gastric Cancer Metastasis and Treatment
    J Cancer Metastasis Treat 2018;4:10. | doi:10.20517/2394-4722.2017.79
    Published on: 28 Feb 2018  | Viewed:827  | Downloaded:93
    +HTML| PDF
  • Review|Open Access

    Therapeutic targets against gastric cancer stem cells interacting with tumor microenvironment

    Tomoyuki Uchihara , Takatsugu Ishimoto , Atsuko Yonemura , Hideo Baba
    Gastric cancer (GC) is a major cause of cancer-related deaths worldwide. The existence of cancer stem cells (CSCs) is known to be the main reason for resistance to anticancer agents as well as for the development of distant metastases. Although CSCs themselves harbor self-renewal and differentiation abilities, the tumor microenvironment that surrounds CSCs provides secreted factors and supports angiogenesis and is thus responsible for the maintenance of their CSC properties. The current review provides information regarding the impact of the tumor microenvironment on gastric CSCs, which... Read more
    This article belongs to the Special Issue Reviews of Gastric Cancer Metastasis and Treatment
    J Cancer Metastasis Treat 2018;4:9. | doi:10.20517/2394-4722.2017.81
    Published on: 26 Feb 2018  | Viewed:764  | Downloaded:85
    +HTML| PDF
  • Review|Open Access

    Significance of peritoneal lavage cytology based on genetic signatures in gastric cancer

    Tasuku Matsuoka , Masakazu Yashiro
    Peritoneal metastasis is the most common pattern of recurrence and the most frequent cause of death after surgery in patients with gastric cancer. Peritoneal free cancer cells disseminated from the primary lesion site have been considered the main cause of peritoneal metastasis. Peritoneal lavage cytological examination (PLC) has been shown to be an independent predictor of gastric cancer relapse after curative resection and poor overall survival. However, the conventional cytological examinations have high rates of false-positive and false-negative findings. To improve the sensitivity,... Read more
    This article belongs to the Special Issue Reviews of Gastric Cancer Metastasis and Treatment
    J Cancer Metastasis Treat 2018;4:6. | doi:10.20517/2394-4722.2017.85
    Published on: 9 Feb 2018  | Viewed:780  | Downloaded:60
    +HTML| PDF
  • Review|Open Access

    Gastric cancer: prevention and treatment of peritoneal metastases

    Paul H. Sugarbaker
    Gastric cancer is an aggressive malignancy that may metastasize through the bloodstream to the liver, through lymphatics to regional lymph nodes, or by penetration of the peritoneal lining of the stomach to result in seeding of the abdominal and pelvis surfaces. Peritoneal metastases are the most common mode of cancer dissemination. Technologies to prevent or treat peritoneal metastases from advanced gastric cancer are presented in this manuscript. The world’s literature, both recent and over the past three decades, was reviewed in order to identify publications that present information... Read more
    This article belongs to the Special Issue Reviews of Gastric Cancer Metastasis and Treatment
    J Cancer Metastasis Treat 2018;4:7. | doi:10.20517/2394-4722.2017.67
    Published on: 9 Feb 2018  | Viewed:1602  | Downloaded:108
    +HTML| PDF
  • Original Article|Open Access

    Gastric cancer treated with pressurized intraperitoneal aerosol chemotherapy: revising an option for peritoneal carcinomatosis

    Filipa Macedo , Kátia Ladeira , Adhemar Longatto-Filho , Sandra F. Martins
    Aim: Gastric cancer is the cancer with the highest rate of peritoneal metastization and this type of spread is associated with a higher death rate compared to distant organ metastasis. The systemic chemotherapy has a minimal effect in peritoneal metastasis so new types of treatment have emerged. The authors revised the main studies done in pressurized intraperitoneal aerosol chemotherapy (PIPAC) and presented the main conclusions. Methods: A PubMed search was conducted focusing on PIPAC in gastric cancer. The MeSH database was searched with the terms: “Gastric cancer [MeSH] and... Read more
    This article belongs to the Special Issue Reviews of Gastric Cancer Metastasis and Treatment
    J Cancer Metastasis Treat 2018;4:8. | doi:10.20517/2394-4722.2017.72
    Published on: 9 Feb 2018  | Viewed:977  | Downloaded:77
    +HTML| PDF
  • Review|Open Access

    Bacteria in cancer therapy: beyond immunostimulation

    Wheeler Torres , Víctor Lameda , Luis Carlos Olivar , Carla Navarro , Jorge Fuenmayor , Adrián Pérez , Andres Mindiola , Milagros Rojas , María Sofía Martínez , Manuel Velasco , Joselyn Rojas , Valmore Bermudez
    Currently, conventional therapies in cancer are improving; chemotherapy, radiotherapy and surgery have increased survival significantly. New therapies have arisen with the same goal; immunotherapy has appeared as a promising option in the fight against cancer stimulating the immune system by inducing innate and adaptive responses. These responses include release of pro-inflammatory cytokines, making the immune system capable to eliminate or protect against multiple tumors. Nowadays, many of these therapies are being used in clinical settings, such as checkpoint inhibitors, monoclonal anti... Read more
    J Cancer Metastasis Treat 2018;4:4. | doi:10.20517/2394-4722.2017.49
    Published on: 24 Jan 2018  | Viewed:4146  | Downloaded:374
    +HTML| PDF
Journal of Cancer Metastasis and Treatment Print ISSN: 2394-4722; Online ISSN: 2454-2857
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.